ArticleTransactions of the Indian National Academy of Engineering : an international journal of engineering and technology2020
Blood Plasma Microfluidic Device: Aiming for the Detection of COVID-19 Antibodies Using an On-Chip ELISA Platform.
Article in Transactions of the Indian National Academy of Engineering : an international journal of engineering and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Microfluidic Blood Separation: Key Technologies and Critical Figures of Merit.Micromachines · 2023Review
- Open multi-organ communication device for easy interrogation of tissue slices.Lab on a chip · 2023Article
- Portable Surface Plasmon Resonance Detector for COVID-19 Infection.Sensors (Basel, Switzerland) · 2023Article
- Investigation and comparison of graphene nanoribbon and carbon nanotube based SARS-CoV-2 detection sensors: An ab initio study.Physica. B, Condensed matter · 2023Article
- A comprehensive review of COVID-19 detection techniques: From laboratory systems to wearable devices.Computers in biology and medicine · 2022Review
- Microfluidics-Based Biosensing Platforms: Emerging Frontiers in Point-of-Care Testing SARS-CoV-2 and Seroprevalence.Biosensors · 2022Review
- Cardiac biomarkers and detection methods for myocardial infarction.Molecular & cellular toxicology · 2022Review
- Automated ELISA On-Chip for the Detection of Anti-SARS-CoV-2 Antibodies.Sensors (Basel, Switzerland) · 2021Article
- Review of Current COVID-19 Diagnostics and Opportunities for Further Development.Frontiers in medicine · 2021Review
- Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19).Emergent materials · 2021Review
- Nucleic Acid and Immunological Diagnostics for SARS-CoV-2: Processes, Platforms and Pitfalls.Diagnostics (Basel, Switzerland) · 2020Review
- The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis.Frontiers in microbiology · 2020Review
- PREFACE on the Special Issue 'Technologies for Fighting COVID-19'.Transactions of the Indian National Academy of Engineering : an international journal of engineering and technology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a public health emergency of international concern. Detection of SARS-CoV-2 virus is an important step towards containing the virus spread. Although viral detection using molecular diagnostic methods is quite common and efficient, these methods are prone to errors, laborious and time consuming. There is an urgent need for blood-based tests which are simple to use, accurate, less time consuming, portable and cost-effective. Human blood plasma contains water, proteins, organic and in-organic substances including bacteria and viruses. Blood plasma can be effectively used to detect COVID-19 antibodies. The immune system generates antibodies (IgM/IgG proteins) in response to the virus and identification of these antibodies is related to the presence of the infection in the patient in the past. Therefore, detecting and testing the presence of these antibodies will be extremely useful for monitoring and surveillance of the population (Petherick, Lancet 395:1101-1102, 2020). Herein, we describe and propose a microfluidic ELISA (enzyme-linked immunosorbent assay) system to detect COVID-19 antibodies on a lab-on-chip platform. We propose to first separate plasma from whole human blood using a microfluidic device and subsequently perform the detection of antibodies in the separated plasma using a semi-automated on-chip ELISA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.